Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours.

Changes in WBC and monocyte subsets during sunitinib treatment All WBC types, except lymphocytes and basophils, showed highly significant changes during the first three cycles of sunitinib, most notably a decrease in monocytes (greater than for any of the other WBC types, with the exception of that for neutrophils on C1D28; Wilcoxon signed-rank test; Figure 2A , and Supplementary Tables S3 and S4 ).

also in 132,142 other papers

Patients with pNET also showed a trend towards higher VEGF levels.

also in 53,322 other papers